Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

July 08, 2008 01:30 ET | Source: Novartis Pharma AG

Novartis completes acquisition of 25% stake in Alcon from Nestlé, first step toward majority ownership of the world leader in eye care

Strong strategic fit with Novartis thanks to Alcon's pharmaceutical, surgical and consumer eye care products businesses Basel, July 8, 2008 - Novartis has acquired a 25% stake in Alcon Inc. (NYSE:...
July 08, 2008 00:35 ET | Source: Novartis Pharma AG

Novartis completes acquisition of 25% stake in Alcon from Nestlé, first step toward majority ownership of the world leader in eye care

Strong strategic fit with Novartis thanks to Alcon's pharmaceutical, surgical and consumer eye care products businesses Basel, July 8, 2008 - Novartis has acquired a 25% stake in Alcon Inc. (NYSE:...
June 24, 2008 01:15 ET | Source: Novartis Pharma AG

Novartis Institute for Tropical Diseases and Global Alliance for TB Drug Development announce five-year collaboration targeted to accelerate TB treatment R&D

The NITD and the TB Alliance's collaboration aims to move projects quickly from the research phase through the translational stage and into development Both partners will leverage their broad...
June 17, 2008 01:15 ET | Source: Novartis Pharma AG

Rasilez®[*] ASPIRE HIGHER clinical program expands to 35,000 patients in 14 trials, the largest cardio-renal outcomes program ever

Novartis to study organ protection potential of Rasilez beyond documented ability to provide powerful blood pressure reductions that last beyond 24 hours[1],[2] Three megatrials explore...
June 13, 2008 01:30 ET | Source: Novartis Pharma AG

Higher initial dose of Glivec achieved better early responses than standard dose for patients with chronic myeloid leukemia

* Embargoed until 8:00 am CET * Efficacy and safety profile in large randomized Phase III study consistent with landmark IRIS trial, which established Glivec as standard of care Study did...
June 12, 2008 01:15 ET | Source: Novartis Pharma AG

Novartis recommends rejection of ''mini-tender'' offer by TRC Capital for American Depositary Shares

Conditional offer made by TRC Capital Corporation for up to two million Novartis American Depositary Shares Novartis recommends against shareholders tendering their shares in response to TRC...
June 05, 2008 01:15 ET | Source: Novartis Pharma AG

FDA broadens US indication for once-yearly Reclast® as only osteoporosis treatment approved for prevention of fractures after a hip fracture

Revised label includes data showing 35% reduction in new clinical fractures in patients treated with Reclast following recent hip fracture[1] Few patients currently receive osteoporosis treatment...
June 04, 2008 17:00 ET | Source: Novartis Pharma AG

New data show potential of Rasilez®* to protect kidneys from damage independent of its proven ability to lower blood pressure

AVOID study shows potential kidney protection benefits of Rasilez in type 2 diabetic patients with kidney disease and high blood pressure[1] Rasilez reduced albuminuria, a key indicator of...
June 04, 2008 01:30 ET | Source: Novartis Pharma AG

Novartis gains rights to promising hospital antibiotic in clinical development through full acquisition of Protez Pharmaceuticals

Acquisition of Protez Pharmaceuticals provides rights to PZ-601 and further strengthens specialty medicines development portfolio in hospital infections PZ-601 a novel broad-spectrum antibiotic...
June 04, 2008 01:15 ET | Source: Novartis Pharma AG

Novartis presents full pipeline of novel vaccines addressing significant unmet needs

Late stage development pipeline with Menveo and MenB vaccines creating meningococcal vaccine franchise with strong growth potential Novartis leverages research excellence with first in class...